Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 11,338 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma
Interventions: Bevacizumab, Carboplatin, Paclitaxel, AG-013736 (axitinib); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 22
States / cities: Baton Rouge, Louisiana • Pittsfield, Massachusetts • Columbus, Mississippi + 14 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Petosemtamab, Investigator's Choice; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 59
States / cities: Mobile, Alabama • Prescott, Arizona • Scottsdale, Arizona + 51 more

Conditions: Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions: Personalized Treatment Recommendations, Standard patient-physician counseling interaction; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Neutropenia, Sarcoma
Interventions: filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, topotecan hydrochloride, vincristine sulfate, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 35 more

Conditions: Dry Eye
Interventions: Artificial Tears; Other
Lead sponsor: Allergan; Industry
Eligibility: 40 Years and older
Enrollment: 284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 17
States / cities: Little Rock, Arkansas • Mission Hills, California • Rancho Mirage, California + 14 more

Conditions: Bradycardia
Interventions: Not listed
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 2,013 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 83
States / cities: Birmingham, Alabama • Prescott, Arizona • Little Rock, Arkansas + 80 more

Conditions: Diabetic Retinopathy
Interventions: Laser Photocoagulation, Bevacizumab; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more

Conditions: Male Infertility
Interventions: new device against ambient electromagnetic radiation, sham device against ambient electromagnetic radiation; Device
Lead sponsor: Waveguard GmbH; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Interventions: denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more

Conditions: Stress Disorders, Post-Traumatic, Substance Use Disorders
Interventions: Prolonged Exposure Therapy; Behavioral
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: San Diego, California • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Breast Cancer
Interventions: celecoxib, vinorelbine ditartrate; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Kidney Injury
Interventions: BCT197 Part A, Placebo, BCT197 Part B; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Orange, California • Saginaw, Michigan • Lincoln, Nebraska + 3 more

Conditions: Heart Failure
Interventions: Alleviant ALV1 System, Sham-Control; Device · Other
Lead sponsor: Alleviant Medical, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 56
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 50 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Magnetic Resonance Imaging, Trametinib Dimethyl Sulfoxide, Uprosertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Type 2 Diabetes, BMI Greater Than 30
Interventions: 31P-MRS and MRI; Radiation
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 45 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 40
States / cities: Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more

Conditions: Vaccines, Meningococcal Vaccines
Interventions: rLP2086 + MCV4 + Tdap, MCV4 + Tdap + saline, rLP2086 + saline; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 12 Years
Enrollment: 2,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 117
States / cities: Birmingham, Alabama • Daphne, Alabama • Chandler, Arizona + 73 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Notapplicable; Other
Lead sponsor: Actelion; Industry
Eligibility: Not listed
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 105
States / cities: Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more

Conditions: Meningeal Neoplasms
Interventions: Intrathecal (injected into the spinal fluid) DepoCyt, Intrathecal methotrexate, Intrathecal cytarabine (also known as ara-C); Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 21
States / cities: Phoenix, Arizona • Berkeley, California • Los Angeles, California + 18 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Calaspargase pegol (S95015); Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 22 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more

Conditions: SARS-CoV2 Infection
Interventions: Remdesivir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
U.S. locations: 165
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more

Conditions: Myopia, Myopic Astigmatism
Interventions: EVO ICL; Device
Lead sponsor: Staar Surgical Company; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Honolulu, Hawaii • Overland Park, Kansas • Omaha, Nebraska + 5 more

Conditions: Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions: Adagrasib, nab-Sirolimus; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Cleveland, Ohio • Nashville, Tennessee • Houston, Texas

Search by objective public record fields.

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

A Natural History Study of Patients With Dry Eye

P3: Pacemaker Patient Profiling Study

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

Validation of New Devices Against Ambient Electromagnetic Radiation

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Massed Prolonged Exposure for PTSD in Substance Use Treatment

Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

Alleviant ALLAY-HF Study

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Imaging in Semaglutide Study

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

SPARK-ALL: Calaspargase Pegol in Adults With ALL

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

Post-Market Evaluation of the EVO ICL

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)